AIDS Therapies

gp120-Expressing VSV As AIDS Gene Therapy Vector, Vaccine

Published in AIDS Weekly, August 18th, 1997

An RNA virus engineered to express the HIV-1 gp120 envelope glycoprotein can be used to deliver gene therapies or as a possible AIDS vaccine.

Yale University researchers J. Erik Johnson et al. found a way to get recombinant vesicular stomatitis virus (VSV) to express the HIV-1 envelope: they removed the large cytoplasmic portion of the gp41 glycoprotein and replaced it with the cytoplasmic domain of the VSV transmembrane glycoprotein.

Extra transcription units also engineered into the recombinant VSV resulted in stable, replication competent viruses capable of high-level expression of HIV-1 proteins.

"Our results illustrate that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-08-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry